PMID- 29359457
OWN - NLM
STAT- In-Data-Review
LR  - 20181011
IS  - 1479-828X (Electronic)
IS  - 0004-8666 (Linking)
VI  - 58
IP  - 5
DP  - 2018 Oct
TI  - The levonorgestrel-releasing intrauterine system is associated with a reduction
      in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in
      quality of life in women with suspected endometriosis.
PG  - 560-563
LID - 10.1111/ajo.12773 [doi]
AB  - BACKGROUND AND AIMS: The aim of this study was to investigate the effectiveness
      of a levonorgestrel-releasing intrauterine device (LNG-IUS) in the symptomatic
      relief of pain in women with endometriosis and additionally, to assess the
      changes in women's life quality and serum cancer antigen (CA) 125 levels.
      MATERIALS AND METHODS: All women who had an LNG-IUS inserted for the treatment of
      dysmenorrhea, chronic pelvic pain or both for more than six months over a
      two-year period were included in the study. Each woman was asked to complete
      questionnaires of the Short Form-36 and visual analogue scales (VAS) in the first
      visit and the third, sixth, ninth and twelfth months after the LNG-IUS insertion.
      CA 125 levels were measured at each visit. RESULTS: Forty-five women were
      included in the study. At the end of 12 months, mean dysmenorrhoea VAS score
      decreased from 6.13 to 2.88, mean dsyspareunia VAS score from 6.04 to 2.61 and CA
      125 level from 50.67 to 22.45. Endometriomas reduced in size in six women (mean
      size decreased from 31 to 20 mm) and disappeared in three. CONCLUSIONS: Several
      favourable outcomes were found following LNG-IUS insertion: (i) dyspareunia and
      dysmenorrhoea were clearly reduced; (ii) the size of endometriomas were
      decreased; (iii) CA 125 levels significantly decreased; (iv) a few women
      experienced the typical systemic adverse effects of progestogens; however,
      LNG-IUS-related adverse events were generally tolerable and the discontinuation
      rate was as low as 6.66% (3/45).
CI  - (c) 2018 The Royal Australian and New Zealand College of Obstetricians and
      Gynaecologists.
FAU - Yucel, Nese
AU  - Yucel N
AD  - Department of Obstetrics and Gynaecology, Goztepe Training and Research Hospital,
      Istanbul Medeniyet University, Istanbul, Turkey.
FAU - Baskent, Erdem
AU  - Baskent E
AD  - Department of Obstetrics and Gynaecology, Goztepe Training and Research Hospital,
      Istanbul Medeniyet University, Istanbul, Turkey.
FAU - Karamustafaoglu Balci, Burcin
AU  - Karamustafaoglu Balci B
AUID- ORCID: http://orcid.org/0000-0001-5196-4502
AD  - Department of Obstetrics and Gynaecology, Goztepe Training and Research Hospital,
      Istanbul Medeniyet University, Istanbul, Turkey.
FAU - Goynumer, Gokhan
AU  - Goynumer G
AD  - Department of Obstetrics and Gynecology, Duzce University, Faculty of Medicine,
      Duzce, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20180123
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
OTO - NOTNLM
OT  - CA 125
OT  - Mirena
OT  - contraception
OT  - endometriosis
OT  - levonorgestrel-releasing intrauterine device
OT  - life quality
EDAT- 2018/01/24 06:00
MHDA- 2018/01/24 06:00
CRDT- 2018/01/24 06:00
PHST- 2017/06/18 00:00 [received]
PHST- 2017/12/17 00:00 [accepted]
PHST- 2018/01/24 06:00 [pubmed]
PHST- 2018/01/24 06:00 [medline]
PHST- 2018/01/24 06:00 [entrez]
AID - 10.1111/ajo.12773 [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 2018 Oct;58(5):560-563. doi: 10.1111/ajo.12773. Epub 
      2018 Jan 23.